Tag:
Boehringer Ingelheim
Latest Headlines
Latest Headlines
Boehringer, pharmas turn to social gaming for online outreach
Boehringer Ingelheim wants to create a social game dubbed "Syrum" that would let players tend to virtual R&D projects and traffic in scientific talent and compounds, according to InPharm .
Pradaxa hits blockbuster mark, swelling Boehringer sales
The German company expects "high single digit" growth in revenues for 2012 and another leap in 2013.
J&J looks for workaround to ease Doxil shortage
The idea is to allow its former contract manufacturer to formulate the cancer drug, and then send it elsewhere for filling and packaging.
Bayer gets positive ruling from NICE on Xarelto
NICE has recommended the drug for stroke and embolisms in draft guidance, and final guidance may come in April.
UPDATED: Amylin shares rocket up on report of $3.5B buyout offer by Bristol-Myers
Shares of Amylin Pharmaceuticals ( $AMLN ) rocketed up more than 40% this morning, fueled by a report that the Bydureon developer had turned down a $22 per share buyout offer from Bristol-Myers Squibb ( $BMY ).
Pradaxa patient's death draws more scrutiny of bleeding risks
The case of a Pradaxa user who died after a minor fall is raising more questions about the drug's safety.
Boehringer Ingelheim spends €17M on expansion in Germany, Vienna
Boehringer Ingelheim has invested €17 million expanding plants in Biberach, Germany, and Vienna.
Pradaxa, Xarelto gain reprieve as FDA delays Eliquis decision
Pfizer ( $PFE ) and Bristol-Myers Squibb ( $BMY ) will have to wait three more months for the FDA's latest word on Eliquis . The anticoagulant drug has some of the strongest data among a new cadre of...
Study flags risk of heart attack, ACS in Pradaxa patients
Another blow to Pradaxa 's prospects: The Boehringer Ingelheim blood thinner has been associated with an increased risk of heart attack. In a new study, Cleveland Clinic researchers found that Pradaxa
Forma scores another Big Pharma deal in $700M J&J cancer pact
Just days after inking an $815 million cancer drug discovery pact with Boehringer Ingelheim, Forma Therapeutics agreed to put its fast-growing small molecule ops to work for J&J's Janssen in a
